Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20016978 | 0.90 | CASP2 (0.51) | MEN1KMT2ANOD1CASP2FAAH | |
| SCHEMBL22022417 | 0.89 | NAMPT (0.38) | MEN1KMT2ANAMPTCNR1NOD1 | |
| SCHEMBL22372632 | 0.87 | MEN1 (0.41) | MEN1KMT2ANAMPTCNR1NOD1 | |
| SCHEMBL18513361 | 0.87 | NMT2 (0.40) | NAMPTCNR1NOD1NMT2NMT1 | |
| SCHEMBL16248536 | 0.84 | NAMPT (0.40) | MEN1KMT2ANAMPTCNR1NOD1 | |
| SCHEMBL24598662 | 0.83 | NAMPT (0.42) | MEN1KMT2ANAMPTCNR1NOD1 | |
| SCHEMBL20099362 | 0.83 | NMT2 (0.53) | NOD1NMT2NMT1EPHX2 | |
| SCHEMBL20234602 | 0.82 | BLM (0.37) | NOD1LMNA | |
| SCHEMBL17589403 | 0.82 | LMNA (0.39) | MEN1KMT2ANAMPTCNR1NOD1 | |
| SCHEMBL20235709 | 0.81 | KDM4E (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10294477-B2 | Compositions and methods for modulating PKK expression | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | MEN1 4586/4885KMT2A 4253/4885NAMPT 951/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | MEN1 3662/4885KMT2A 2674/4885NAMPT 563/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | MEN1 1068/4885KMT2A 849/4885NAMPT 1508/4885 |
| US-10294477-B2 | Compositions and methods for modulating PKK expression | GCKR, PKM, PKLR | MEN1 3267/4885KMT2A 1127/4885NAMPT 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.